Charles Schwab
KRRO icon

Charles Schwab’s Korro Bio KRRO Stock Holding History

Charles Schwab’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Buy
24,110
+10,716
+80% +$133K ﹤0.01% 3324
2026
Q1 		$152K Sell
13,394
-2,935
-18% -$32.3K ﹤0.01% 3332
2025
Q4 		$131K Sell
16,329
-6,772
-29% -$158K ﹤0.01% 3380
2025
Q3 		$1.11M Buy
23,101
+5,325
+30% +$118K ﹤0.01% 2915
2025
Q2 		$222K Sell
17,776
-512
-3% -$7.37K ﹤0.01% 3362
2025
Q1 		$318K Buy
18,288
+790
+5% +$23.4K ﹤0.01% 3191
2024
Q4 		$666K Sell
17,498
-69
-0.4% -$3.55K ﹤0.01% 3053
2024
Q3 		$587K Hold
17,567
– – ﹤0.01% 3107
2024
Q2 		$595K Buy
17,567
+14,420
+458% +$797K ﹤0.01% 3122
2024
Q1 		$283K Buy
+3,147
New +$172K ﹤0.01% 3185
2023
Q4 		– Sell
-467
Closed -$8.55K – 3555
2023
Q3 		$8.55K Hold
467
– – ﹤0.01% 3568
2023
Q2 		$8.08K Hold
467
– – ﹤0.01% 3599
2023
Q1 		$11.8K Hold
467
– – ﹤0.01% 3536
2022
Q4 		$90K Hold
467
– – ﹤0.01% 3275
2022
Q3 		$42K Buy
+467
New +$47.4K ﹤0.01% 3371
2022
Q2 		– Sell
-1,515
Closed -$161K – 3599
2022
Q1 		$161K Sell
1,515
-65
-4% -$12.4K ﹤0.01% 3336
2021
Q4 		$406K Hold
1,580
– – ﹤0.01% 3214
2021
Q3 		$558K Sell
1,580
-2,456
-61% -$967K ﹤0.01% 3112
2021
Q2 		$2.01M Buy
4,036
+61
+2% +$29.8K ﹤0.01% 2712
2021
Q1 		$1.89M Buy
3,975
+120
+3% +$233K ﹤0.01% 2681
2020
Q4 		$6.8M Buy
3,855
+26
+0.7% +$34.3K ﹤0.01% 2072
2020
Q3 		$3.68M Buy
3,829
+2,011
+111% +$2.16M ﹤0.01% 2231
2020
Q2 		$2.11M Buy
1,818
+1,101
+154% +$995K ﹤0.01% 2403
2020
Q1 		$639K Buy
717
+11
+2% +$11.9K ﹤0.01% 2628
2019
Q4 		$620K Buy
+706
New +$549K ﹤0.01% 2742

Other funds holding KRRO

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Charles Schwab's KRRO Position: Q2 2026 in Review

Charles Schwab increased its Korro Bio (KRRO) stake by 80% in Q2 2026, buying an estimated $133K and bringing the position to 24,110 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #3324.

Charles Schwab first reported a position in KRRO in Q4 2019 and has held it in 25 quarters since. The position peaked at $6.8M in Q4 2020. 106 funds tracked by Wall St. Rank hold KRRO as of Q2 2026.

  • Charles Schwab held 24,110 shares of Korro Bio worth $318K as of Q2 2026.
  • Charles Schwab bought 10,716 Korro Bio shares in Q2 2026, an estimated $133K.
  • Korro Bio made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3324 holding.
  • Charles Schwab first reported a position in Korro Bio in Q4 2019 and has held it in 25 quarters since.
  • Charles Schwab's Korro Bio position peaked at $6.8M in Q4 2020.
  • 106 funds tracked by Wall St. Rank held Korro Bio as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.